The Provenge Anchor Is Sinking Dendreon

SEATTLE ( TheStreet) -- Dendreon ( DNDN) troubles, already substantial, just got so much worse.

Sales of the prostate cancer therapy Provenge fell short of the Street's second quarter expectations. The company now says Provenge sales will no longer grow year over year, as expected. Lastly, Dendreon's CFO Greg Schiffman announced his exit from the company at the end of the year.

The deluge of bad news, delivered during Dendreon's second-quarter earnings announcement Thursday night, is sure to raise even more concerns about the company's viability.

Dendreon shares closed Thursday down 1.5 percent to $4.59 but fell another 12 percent to $4.09 in after-hours trading.

Provenge sales in the June quarter totaled $73.3 million, or 8 percent quarter-over-quarter growth, versus Street consensus of $75 million, or 11 percent growth.

Based on patient enrollment trends this summer, Dendreon now say it doesn't expect Provenge sales growth to increase enough to meet its guidance of sales growth for the full year. Provenge use is being negatively impacted by competing prostate cancer drugs marketed by Johnson & Johnson ( JNJ) and Medivation ( MDVN), respectively.

For the first six months of the year, Provenge sales totaled $141 million and the Dendreon would have needed sales of $184 million in the third and fourth quarters. Thursday, the company said such sales growth is unlikely.

If there's any consolation to the disappointing retreat in Provenge guidance, it's that the Street didn't believe the company anyway, already expecting year over year sales to fall by 3 percent.

Dendreon ended the second quarter with $280.6 million in cash. Looming ahead is $545 million in convertible debt due in 2016.

Net loss in the second quarter was $68.8 million, or 45 cents per share, compared to a net loss of $96.1 million, or 65 cents per share, for the same period in 2012.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes